Pharmaceuticals & Life Sciences

Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded via Business Combination with Moringa Acquisition Corp

Moringa Acquisition Corp (Nasdaq: MACA) (“Moringa”), a special purpose acquisition company, announces it has entered into a business combination agreement with Silexion Ltd. (“Silexion”), a clinical-stage, oncology-focused biotechnology company, that would result in Silexion becoming publicly listed on the Nasdaq. The business combination provides for Silexion’s pre-transaction equity value to be $62.5 million, based on

Silexion, a Clinical-Stage, Oncology-Focused Biotechnology Company, to Become Publicly Traded via Business Combination with Moringa Acquisition Corp Read More »

Will the Return of Pharma Mergers and Acquisitions Continue? Q&A with Arthur Wong, Managing Director, Healthcare, S&P Global Ratings

After the COVID boom, mergers and acquisitions (M&A) in pharma and life sciences saw a decline as the industry corrected itself. Last year, M&A started to make a comeback. Arthur Wong, managing director, healthcare, at S&P Global Ratings, spoke with Pharmaceutical Executive and provided an in-depth analysis of how the trend is continuing and adapting

Will the Return of Pharma Mergers and Acquisitions Continue? Q&A with Arthur Wong, Managing Director, Healthcare, S&P Global Ratings Read More »

Emerging Artificial Intelligence Applications in Preclinical Drug Development

Drug development is a long and expensive endeavor with a low success rate. A billion dollar market, artificial intelligence (AI) applications in preclinical research are being adopted by biopharma manufacturers and CROs as well as serving as the core platform of novel biotechs and service providers. AI in the life sciences has evolved from its

Emerging Artificial Intelligence Applications in Preclinical Drug Development Read More »

Infinity Pharmaceuticals Sells Substantially All of Its Assets to Healthcare Investment Firm

SSG Capital Advisors served as the investment banker to Infinity Pharmaceuticals in the sale of substantially all its assets to a healthcare investment firm. The sale was effectuated through a Chapter 11 Section 363 process in the U.S. Bankruptcy Court for the District of Delaware. The transaction closed in February 2024. Founded in 1995 and

Infinity Pharmaceuticals Sells Substantially All of Its Assets to Healthcare Investment Firm Read More »

Q4 2023 Update: Private Equity Deals in the Pharmaceutical Industry in the US

In the US pharmaceutical industry, there were 31 private equity deals announced in Q4 2023, worth a total value of $700.5m, according to GlobalData’s Deals Database. The $375m management buy-in (mbi) ZimVie by H.I.G. Capital was the industry’s largest disclosed deal. In value terms, private equity deal activity in the US decreased by 84% in

Q4 2023 Update: Private Equity Deals in the Pharmaceutical Industry in the US Read More »

Scroll to Top